Get the Stockscreener App
1.40
0.00%
0.00
Aprea Therapeutics Inc stock is traded at $1.40, with a volume of 45,297.
It is up +0.00% in the last 24 hours and down -6.67% over the past month.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
See More
Previous Close:
$1.40
Open:
$1.4
24h Volume:
45,297
Relative Volume:
0.61
Market Cap:
$8.16M
Revenue:
-
Net Income/Loss:
$-14.29M
P/E Ratio:
-0.3509
EPS:
-3.99
Net Cash Flow:
$-12.27M
1W Performance:
+4.48%
1M Performance:
-6.67%
6M Performance:
-24.32%
1Y Performance:
-64.29%
1-Day Range:
$1.39
$1.45
1-Week Range:
$1.31
$1.49
52-Week Range:
$1.31
$5.00
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
215-948-4119
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
1.40 | 8.16M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.52 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.42 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.79 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.21 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.05 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
Aprea Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Tools to assess Aprea Therapeutics Inc.’s risk profileJuly 2025 Selloffs & Trade Opportunity Analysis Reports - newser.com
Will Aprea Therapeutics Inc. stock outperform value stocksJuly 2025 Trends & AI Driven Price Forecasts - newser.com
Why Aprea Therapeutics Inc. stock could outperform in 2025Trade Exit Summary & Low Risk High Win Rate Picks - newser.com
Is Aprea Therapeutics Inc. stock attractive for growth ETFsDividend Hike & Risk Controlled Daily Trade Plans - newser.com
Risk vs reward if holding onto Aprea Therapeutics Inc.Portfolio Risk Summary & Free Technical Pattern Based Buy Signals - newser.com
Aprea Therapeutics Reports Early Signs of Activity in APR-1051 Cancer Trial - MyChesCo
Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors - MSN
Is Aprea Therapeutics Inc. stock poised for growthMarket Performance Summary & Advanced Technical Analysis Signals - newser.com
Aprea Therapeutics, Inc. (APRE) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Aprea Therapeutics, Inc.Common Stock (Nasdaq:APRE) Stock Quote | PRN_FinancialWrapper | PR Newswire - FinancialContent
How Aprea Therapeutics Inc. stock reacts to global recession fearsQuarterly Investment Review & Verified Technical Trade Signals - Fundação Cultural do Pará
Will Aprea Therapeutics Inc. stock outperform tech sector in 2025Market Performance Report & Low Drawdown Investment Ideas - fcp.pa.gov.br
Meme Stocks: How Aprea Therapeutics Inc. stock performs in weak economy2025 Earnings Surprises & Accurate Technical Buy Alerts - Fundação Cultural do Pará
Update Recap: Will Aprea Therapeutics Inc. stock deliver shareholder value2025 Earnings Surprises & Low Risk Entry Point Tips - fcp.pa.gov.br
Aprea Therapeutics Advances with Phase 1 Study of APR-1051 in Solid Tumors - TipRanks
Aprea’s WEE1 inhibitor shows disease stabilization in early trial - Investing.com
Aprea’s WEE1 inhibitor shows disease stabilization in early trial By Investing.com - Investing.com South Africa
Aprea Therapeutics Reports Promising Trial Results for APR-1051 - TipRanks
Aprea sees early activity in APR-1051 Wee1 trial - MarketScreener
Aprea Therapeutics Provides Clinical Update on ACESOT-1051 Trial - TradingView
Aprea Therapeutics Reports Promising Early Results for APR-1051 in Phase 1 Trial for Advanced Solid Tumors at AACR-NCI-EORTC Conference - Quiver Quantitative
Aprea Therapeutics IncDose Escalation Cont - 富途牛牛
Aprea Therapeutics (NASDAQ: APRE) advances APR-1051; three of four stable at 100 mg - Stock Titan
Can Aprea Therapeutics Inc. rally from current levels2025 Analyst Calls & Consistent Profit Trade Alerts - newser.com
Sentiment analysis tools applied to Aprea Therapeutics Inc.Chart Signals & Reliable Entry Point Alerts - newser.com
Aprea Therapeutics, Inc. (APRE) stock forecast and price target - Yahoo! Finance UK
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):